{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INCB050465", "query": { "intervention": "INCB050465" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INCB050465&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T05:38:27.813Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02718300", "title": "A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MPN (Myeloproliferative Neoplasms)" ], "interventions": [ { "name": "Parsaclisib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2017-02-08", "completion_date": "2022-04-29", "has_results": true, "last_update_posted_date": "2024-05-01", "last_synced_at": "2026-09-02T05:38:27.813Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02718300" }, { "nct_id": "NCT03538041", "title": "A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autoimmune Hemolytic Anemia" ], "interventions": [ { "name": "Parsaclisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2018-11-21", "completion_date": "2024-04-02", "has_results": true, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-09-02T05:38:27.813Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Minneapolis, Minnesota • St Louis, Missouri + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03538041" }, { "nct_id": "NCT04323956", "title": "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ann Arbor Stage II Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage II Follicular Lymphoma", "Ann Arbor Stage II Marginal Zone Lymphoma", "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage III Follicular Lymphoma", "Ann Arbor Stage III Marginal Zone Lymphoma", "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IV Follicular Lymphoma", "Ann Arbor Stage IV Marginal Zone Lymphoma", "Diffuse Large B-Cell Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Indolent Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Parsaclisib", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2020-06-15", "completion_date": "2028-05-16", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-09-02T05:38:27.813Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04323956" }, { "nct_id": "NCT04551053", "title": "To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelofibrosis", "Primary Myelofibrosis", "Post Essential Thrombocythemia Myelofibrosis", "Post Polycythemia Vera Myelofibrosis" ], "interventions": [ { "name": "parsaclisib", "type": "DRUG" }, { "name": "ruxolitinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2021-05-26", "completion_date": "2024-08-21", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-09-02T05:38:27.813Z", "location_count": 35, "location_summary": "Berkeley, California • Fresno, California • Los Angeles, California + 27 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04551053" }, { "nct_id": "NCT03627065", "title": "A Study of INCB050465 in Primary Sjögren's Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Sjögren's Syndrome" ], "interventions": [ { "name": "Parsaclisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2019-02-28", "completion_date": "2020-01-02", "has_results": true, "last_update_posted_date": "2021-08-13", "last_synced_at": "2026-09-02T05:38:27.813Z", "location_count": 4, "location_summary": "Miami, Florida • Lawrenceville, Georgia • Wheaton, Maryland + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Lawrenceville", "state": "Georgia" }, { "city": "Wheaton", "state": "Maryland" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03627065" }, { "nct_id": "NCT02646748", "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer (CRC)", "Endometrial Cancer", "Melanoma", "Head and Neck Cancer", "Lung Cancer", "MMR-deficient Tumors", "Breast Cancer", "Pancreatic Cancer", "Renal Cell Carcinoma (RCC)", "Solid Tumors", "UC (Urothelial Cancer)" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "itacitinib", "type": "DRUG" }, { "name": "INCB050465", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2016-01-25", "completion_date": "2020-11-20", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-09-02T05:38:27.813Z", "location_count": 17, "location_summary": "San Francisco, California • Santa Monica, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02646748" }, { "nct_id": "NCT03235544", "title": "A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Parsaclisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2017-11-20", "completion_date": "2024-04-30", "has_results": true, "last_update_posted_date": "2025-03-18", "last_synced_at": "2026-09-02T05:38:27.813Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Santa Rosa, California • Aurora, Colorado + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Brooksville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03235544" }, { "nct_id": "NCT03039114", "title": "Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Parsaclisib", "type": "DRUG" }, { "name": "Hexal", "type": "DRUG" }, { "name": "Gazyvaro", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2017-02-15", "completion_date": "2021-03-30", "has_results": false, "last_update_posted_date": "2025-08-21", "last_synced_at": "2026-09-02T05:38:27.813Z", "location_count": 6, "location_summary": "Gilbert, Arizona • La Jolla, California • Fairway, Kansas + 3 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03039114" }, { "nct_id": "NCT04831996", "title": "To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "parsaclisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "82 Years", "sex": "ALL", "summary": "18 Years to 82 Years" }, "enrollment_count": 48, "start_date": "2021-05-04", "completion_date": "2022-07-08", "has_results": false, "last_update_posted_date": "2022-08-17", "last_synced_at": "2026-09-02T05:38:27.813Z", "location_count": 4, "location_summary": "Tustin, California • Hialeah, Florida • Orlando, Florida + 1 more", "locations": [ { "city": "Tustin", "state": "California" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04831996" }, { "nct_id": "NCT02559492", "title": "Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "INCB050465", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2015-11", "completion_date": "2019-08-18", "has_results": false, "last_update_posted_date": "2019-09-25", "last_synced_at": "2026-09-02T05:38:27.813Z", "location_count": 11, "location_summary": "Duarte, California • Denver, Colorado • New Haven, Connecticut + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02559492" } ] }